Ascelia Pharma - Presentation of H1 2025 Results

You can already now sign up for the event and send in your questions. You don’t have to participate live to submit questions for the event.

Join us for a live presentation with Deputy CEO Julie Waras Brogren from Ascelia Pharma on 22 August 2025 at 10:00 AM CEST when she presents the financial results for H1 2025. You will have the opportunity to ask questions and gain insights into the company’s latest developments.

During the quarter, Ascelia Pharma participated in several conferences and presented Phase 3 data on Orviglance®. As previously communicated, the company expects to submit the New Drug Application (NDA) for Orviglance to the FDA following the end of the half-year period.

About Ascelia Pharma
Ascelia Pharma is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. Ascelia Pharma has two drug candidates in clinical development – Orviglance® (Mangoral) and Oncoral. The company is headquartered in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE).

Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a DigitalIR/Corporate Visibility agreement./Claus Thestrup, 10.39, 8 July 2025.